Clinical evaluation of thrombotic microangiopathy: Identification of patients with suspected atypical hemolytic uremic syndrome

Medicine & Life Sciences

• Atypical Hemolytic Uremic Syndrome 100%
• Thrombotic Microangiopathies 90%
• eculizumab 22%
• Complement Activation 16%
• Malignant Hypertension 10%
• Antibodies, Monoclonal, Humanized 9%
• Complement System Proteins 9%
• Plasma Exchange 9%
• Art 8%
• Haemolytic Anaemia 8%
• Mutation 8%
• Hematopoietic Stem Cell Transplantation 7%
• Thrombocytopenia 6%
• Systemic Lupus Erythematosus 6%
• Inborn Genetic Diseases 6%
• Therapeutics 4%
• Physicians 4%
• Pregnancy 4%
• Morbidity 4%
• Kidney 3%
• Mortality 3%
• Child 3%